Raymond James Financial Inc. bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 329,980 shares of the biopharmaceutical company's stock, valued at approximately $6,887,000. Raymond James Financial Inc. owned 0.28% of Catalyst Pharmaceuticals as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Steward Partners Investment Advisory LLC purchased a new stake in Catalyst Pharmaceuticals during the 4th quarter worth approximately $27,000. Larson Financial Group LLC increased its position in shares of Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 2,994 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth approximately $65,000. KBC Group NV raised its stake in Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after purchasing an additional 1,542 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new position in Catalyst Pharmaceuticals in the 4th quarter valued at $134,000. Institutional investors and hedge funds own 79.22% of the company's stock.
Catalyst Pharmaceuticals Trading Down 0.2 %
Catalyst Pharmaceuticals stock traded down $0.06 during mid-day trading on Tuesday, hitting $25.68. The company's stock had a trading volume of 993,574 shares, compared to its average volume of 1,063,389. The stock's fifty day moving average is $22.46 and its two-hundred day moving average is $21.67. The firm has a market capitalization of $3.12 billion, a PE ratio of 21.72, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.47 and a 1 year high of $26.16.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on CPRX. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Robert W. Baird increased their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Bank of America reaffirmed a "buy" rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $32.29.
Get Our Latest Stock Analysis on Catalyst Pharmaceuticals
Insider Activity at Catalyst Pharmaceuticals
In other news, insider Gary Ingenito sold 44,904 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now directly owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company's stock, valued at $4,333,200.72. The trade was a 25.04 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.
About Catalyst Pharmaceuticals
(
Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Further Reading
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
